Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Genmab Announces Financial Results for the First Nine Months of 2024
11:02am, Wednesday, 06'th Nov 2024
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY ®
Genmab: Looking To Manage My Position Around Q3 Earnings
03:17am, Wednesday, 06'th Nov 2024
Genmab's robust pipeline, strategic partnerships, and strong 2023 performance, led by DARZALEX and EPKINLY, bolster my bullish conviction despite ongoing legal disputes with Johnson & Johnson. The com
Genmab to Present at Jefferies London Healthcare Conference
01:11pm, Tuesday, 05'th Nov 2024
Media Release COPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief Executive Officer , Jan van de Winkel, Ph.D. and C hief F inancial O fficer , Anthony Pag
Media Release COPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin's lymphoma (N
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?
10:45am, Wednesday, 16'th Oct 2024
Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.
Is Genmab (GMAB) Stock Undervalued Right Now?
10:45am, Tuesday, 15'th Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
06:25am, Tuesday, 15'th Oct 2024
Company Announcement Net sales of DARZALEX ® in the third quarter of 2024 totaled USD 3,016 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, D
GMAB or INCY: Which Is the Better Value Stock Right Now?
12:48pm, Tuesday, 08'th Oct 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Incyte (INCY). But which of these two stocks presents inve
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
10:35am, Tuesday, 08'th Oct 2024
Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Major Shareholder Announcement
01:55pm, Friday, 04'th Oct 2024
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Mark
Grant of Restricted Stock Units and Warrants to Employees in Genmab
03:17pm, Thursday, 26'th Sep 2024
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employee
Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion
Capital Increase in Genmab as a Result of Employee Warrant Exercise
04:06pm, Tuesday, 10'th Sep 2024
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The i
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
12:26pm, Monday, 26'th Aug 2024
Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
11:55am, Friday, 23'rd Aug 2024
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, w
